Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Med Chem ; 28(13): 2577-2653, 2021.
Article in English | MEDLINE | ID: mdl-32819230

ABSTRACT

Chronic obstructive pulmonary disease (COPD) represents a heightened inflammatory response in the lung generally resulting from tobacco smoking-induced recruitment and activation of inflammatory cells and/or activation of lower airway structural cells. Several mediators can modulate activation and recruitment of these cells, particularly those belonging to the chemokines (conventional and atypical) family. There is emerging evidence for complex roles of atypical chemokines and their receptors (such as high mobility group box 1 (HMGB1), antimicrobial peptides, receptor for advanced glycosylation end products (RAGE) or toll-like receptors (TLRs)) in the pathogenesis of COPD, both in the stable disease and during exacerbations. Modulators of these pathways represent potential novel therapies for COPD and many are now in preclinical development. Inhibition of only a single atypical chemokine or receptor may not block inflammatory processes because there is redundancy in this network. However, there are many animal studies that encourage studies for modulating the atypical chemokine network in COPD. Thus, few pharmaceutical companies maintain a significant interest in developing agents that target these molecules as potential antiinflammatory drugs. Antibody-based (biological) and small molecule drug (SMD)-based therapies targeting atypical chemokines and/or their receptors are mostly at the preclinical stage and their progression to clinical trials is eagerly awaited. These agents will most likely enhance our knowledge about the role of atypical chemokines in COPD pathophysiology and thereby improve COPD management.


Subject(s)
HMGB1 Protein , Pulmonary Disease, Chronic Obstructive , Animals , Chemokines , Lung , Pulmonary Disease, Chronic Obstructive/drug therapy , Pulmonary Disease, Chronic Obstructive/etiology , Receptors, Chemokine
2.
Expert Opin Emerg Drugs ; 25(4): 419-431, 2020 12.
Article in English | MEDLINE | ID: mdl-32882146

ABSTRACT

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by chronic bronchitis, emphysema, and remodeling. Its prevalence is increasing worldwide; however, there are few effective therapies, and none of the treatments currently available prevent the progression of the disease or target all of the hallmark features. The development and progression of COPD are heterogeneous, which has hampered the development of new therapies. AREAS COVERED: In this review, we cover the emergence of the improvement of existing classes of drugs including glucocorticoids, ß2-adrenoceptor agonists, phosphodiesterase inhibitors, PDE4 selective inhibitors, PDE3/PDE4 inhibitors, protease inhibitors, recombinant α1-antitrypsin and neutrophil elastase inhibitors. We also highlight new compounds that target recently identified mechanisms of COPD, new dual-action muscarinic antagonists, and ß2-agonists, kinase inhibitors, cytokine modifiers, chemokines modifiers, NF-κB inhibitors, senolytics, antioxidants, inhaled antiviral agents, anti-fibrotic compounds, and compounds stimulating lung regeneration. EXPERT OPINION: Given the myriad of potential therapeutic avenues that can be pursued, careful consideration of the phenotypes/endotypes of COPD patients will be important for personalized treatment options in the future, and a full understanding of disease mechanisms in patient subsets will ensure these emerging therapies are targeted appropriately.


Subject(s)
Drug Design , Drug Development , Pulmonary Disease, Chronic Obstructive/drug therapy , Animals , Bronchodilator Agents/administration & dosage , Disease Progression , Humans , Pulmonary Disease, Chronic Obstructive/physiopathology
3.
Monaldi Arch Chest Dis ; 90(3)2020 Jul 24.
Article in English | MEDLINE | ID: mdl-32702962

ABSTRACT

Diffuse alveolar hemorrhage (DAH) is an acute often life-threatening condition characterized by a variable combination of hemoptysis, dyspnoea, diffuse and bilateral ground glass pulmonary opacities, anemia and hypoxemia, that can be induced by different causes, including several drugs. We report here the case of a 25-year-old woman who has been admitted to our pulmonary clinic for the onset of chest pain, cough and haemoptysis, started one week after her first treatment with alemtuzumab for multiple sclerosis. Computed tomography (CT) scan of the chest at the admission showed diffuse and bilateral ground glass pulmonary opacities. Her symptoms resolved completely without any treatment, after the interruption of alemtuzumab, and CT scan of the chest performed one month later showed total disappearance of the pulmonary opacities.


Subject(s)
Alemtuzumab/adverse effects , Lung Diseases/diagnostic imaging , Lung Injury/chemically induced , Multiple Sclerosis/drug therapy , Tomography, X-Ray Computed/methods , Adult , Alemtuzumab/administration & dosage , Alemtuzumab/therapeutic use , Antineoplastic Agents, Immunological/administration & dosage , Antineoplastic Agents, Immunological/adverse effects , Antineoplastic Agents, Immunological/therapeutic use , Drug-Related Side Effects and Adverse Reactions/complications , Dyspnea/chemically induced , Dyspnea/diagnosis , Female , Hemoptysis/chemically induced , Hemoptysis/diagnosis , Hemorrhage/chemically induced , Hemorrhage/diagnosis , Humans , Lung Diseases/pathology , Lung Injury/complications , Withholding Treatment
4.
Expert Rev Respir Med ; 14(5): 465-483, 2020 05.
Article in English | MEDLINE | ID: mdl-32133884

ABSTRACT

Introduction: Evidence accumulated in the last decade has started to reveal the enormous complexity in the expression, interactions and functions of the large number of different mucins present in the different compartments of the human lower airways. This occurs both in normal subjects and in COPD patients in different clinical phases and stages of severity.Areas covered: We review the known physiological mechanisms that regulate mucin production in human lower airways of normal subjects, the changes in mucin synthesis/secretion in COPD patients and the clinical efficacy of drugs that modulate mucin synthesis/secretion.Expert opinion: It is evident that the old simplistic concept that mucus hypersecretion in COPD patients is associated with negative clinical outcomes is not valid and that the therapeutic potential of 'mucolytic drugs' is under-appreciated due to the complexity of the associated molecular network(s). Likewise, our current knowledge of the effects of the drugs already available on the market that target mucin synthesis/secretion/structure in the lower airways is extremely limited and often indirect and more well-controlled clinical trials are needed in this area.


Subject(s)
Mucins/metabolism , Pulmonary Disease, Chronic Obstructive/metabolism , Humans , Mucus , Pulmonary Disease, Chronic Obstructive/etiology
5.
Curr Opin Pharmacol ; 46: 82-89, 2019 06.
Article in English | MEDLINE | ID: mdl-31207387

ABSTRACT

Inflammation is a central feature of asthma and chronic obstructive pulmonary disease (COPD). Despite recent advances in the knowledge of the pathogenesis of asthma and COPD, much more research on the molecular mechanisms of asthma and COPD are needed to aid the logical development of new therapies for these common and important diseases, particularly in COPD where no new effective treatments currently exist. In the future the role of the activation/repression of different transcription factors and the genetic regulation of their expression in asthma and COPD may be an increasingly important aspect of research, as this may be one of the critical mechanisms regulating the expression of different clinical phenotypes and their responsiveness to therapy, particularly to anti-inflammatory drugs.


Subject(s)
Asthma/drug therapy , Pulmonary Disease, Chronic Obstructive/drug therapy , Transcription Factors/antagonists & inhibitors , Animals , Anti-Inflammatory Agents/therapeutic use , Asthma/metabolism , Bronchodilator Agents/therapeutic use , Humans , Inflammation/drug therapy , Pulmonary Disease, Chronic Obstructive/metabolism , Theophylline/therapeutic use , Transcription Factors/metabolism
6.
Expert Opin Ther Targets ; 23(6): 539-553, 2019 06.
Article in English | MEDLINE | ID: mdl-31079559

ABSTRACT

INTRODUCTION: COPD and lung cancer are leading causes of morbidity and mortality worldwide, and they share a common environmental risk factor in cigarette smoke exposure and a genetic predisposition represented by their incidence in only a fraction of smokers. This reflects the ability of cigarette smoke to induce an inflammatory response in the airways of susceptible smokers. Moreover, COPD could be a driving factor in lung cancer, by increasing oxidative stress and the resulting DNA damage and repression of the DNA repair mechanisms, chronic exposure to pro-inflammatory cytokines, repression of innate immunity and increased cellular proliferation. Areas covered: We have focused our review on the potential pathogenic molecular links between tobacco smoking-related COPD and lung cancer and the potential molecular targets for new drug development by understanding the common signaling pathways involved in COPD and lung cancer. Expert commentary: Research in this field is mostly limited to animal models or small clinical trials. Large clinical trials are needed but mostly combined models of COPD and lung cancer are necessary to investigate the processes caused by chronic inflammation, including genetic and epigenetic alteration, and the expression of inflammatory mediators that link COPD and lung cancer, to identify new molecular therapeutic targets.


Subject(s)
Drug Discovery , Lung Neoplasms/drug therapy , Pulmonary Disease, Chronic Obstructive/drug therapy , Animals , Cigarette Smoking/adverse effects , DNA Damage/physiology , DNA Repair/physiology , Humans , Inflammation/drug therapy , Inflammation/pathology , Lung Neoplasms/pathology , Molecular Targeted Therapy , Oxidative Stress/physiology , Pulmonary Disease, Chronic Obstructive/pathology
7.
COPD ; 15(5): 536-556, 2018 10.
Article in English | MEDLINE | ID: mdl-30468084

ABSTRACT

There are only few human translational studies performed in the area of stem cell research in patients with chronic obstructive pulmonary disease (COPD) and/or pulmonary emphysema. Before progress to clinical trials with stem cells we strongly believe that more human translational studies are essential, otherwise, the clinical rationale would be solely based on limited in vitro and animal studies. In the future, stem cell therapy could be a treatment for this incurable disease. As of now, stem cell therapy is still to be considered as an area of active research, lacking any strong rationale for performing clinical trials in COPD. Although stem cells would be likely to represent a heterogeneous population of cells, the different cell subsets and their importance in the pathogenesis of the different clinical phenotypes need to be fully characterised before progressing to clinical trials. Moreover, the potential side effects of stem cell therapy are underestimated. We should not ignore that some of the most deadly neoplasms are arising from stem cells.


Subject(s)
Pulmonary Disease, Chronic Obstructive/pathology , Pulmonary Disease, Chronic Obstructive/therapy , Pulmonary Emphysema/pathology , Pulmonary Emphysema/therapy , Stem Cell Transplantation/adverse effects , Stem Cells/physiology , Translational Research, Biomedical , Animals , Clinical Trials as Topic , Humans , Low-Level Light Therapy , Mice , Models, Animal , Pulmonary Disease, Chronic Obstructive/economics , Pulmonary Disease, Chronic Obstructive/mortality , Smoking/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL